anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid.
The study will be conducted in a randomized controlled manner. Participants will be divided into groups of 3 equal numbers using the simple randomization method. The control group will not be given exercise. The first intervention group will be given 10-15 minutes of oropharyngeal exercises. In addition to oropharyngeal exercises, the second intervention group will be given 50 minutes of moderate-intensity aerobic exercise at least 3 days a week. Both intervention groups will apply the given exercise program for 8 weeks. All participants will be evaluated 3 times in total, at the beginning of the treatment, at the 4th week and at the 8th week. Epworth Sleepiness Scale, Pittsburgh Sleep Quality Questionnaire, Fatigue Severity Scale, Berlin Questionnaire, 6-minute walk test, Modified Medical Research Council (MMRC) Dyspnea Scale, Functional Results of Sleep Scale (FOSQ) tests will be applied to the participants. Pre- and post-intervention data were statistically analyzed and compared.
Obesity is a leading risk factor for progression and metastasis of many cancers1,2, yet can in some cases enhance survival3-5 and responses to immune checkpoint blockade therapies, including anti-PD-1, which targets PD-1 (encoded by PDCD1), an inhibitory receptor expressed on immune cells6-8. Although obesity promotes chronic inflammation, the role of the immune system in the obesity-cancer connection and immunotherapy remains unclear. It has been shown that in addition to T cells, macrophages can express PD-19-12. Here we found that obesity selectively induced PD-1 expression on tumour-associated macrophages (TAMs). Type I inflammatory cytokines and molecules linked to obesity, including interferon-γ, tumour necrosis factor, leptin, insulin and palmitate, induced macrophage PD-1 expression in an mTORC1- and glycolysis-dependent manner. PD-1 then provided negative feedback to TAMs that suppressed glycolysis, phagocytosis and T cell stimulatory potential. Conversely, PD-1 blockade increased the level of macrophage glycolysis, which was essential for PD-1 inhibition to augment TAM expression of CD86 and major histocompatibility complex I and II molecules and ability to activate T cells. Myeloid-specific PD-1 deficiency slowed tumour growth, enhanced TAM glycolysis and antigen-presentation capability, and led to increased CD8+ T cell activity with a reduced level of markers of exhaustion. These findings show that obesity-associated metabolic signalling and inflammatory cues cause TAMs to induce PD-1 expression, which then drives a TAM-specific feedback mechanism that impairs tumour immune surveillance. This may contribute to increased cancer risk yet improved response to PD-1 immunotherapy in obesity.
The invention discloses a protein bonded with rabbit hemorrhagic disease virus (RHDV) VP60 protein and application thereof. The protein is characterized by comprising at least one sequence which is shown as SEQ ID NO: 1. In the invention, moesin (MSN) which interacts with rabbit hemorrhagic disease virus structural protein VP60 is tagged from a rabbit liver tissue complementary DNA (cDNA) library through a yeast two-hybrid technology. Immunoprecipitation tests verify that the protein has the function of being bonded with virus particles in vitro; and the purified MSN protein can inhibit the agglutination effect of 8 hemagglutination units of virus antigen on human O-shaped erythrocytes. The protein and the rabbit hemorrhagic disease virus are incubated at room temperature; an anti-RHDV negative rabbit is inoculated through oral administration and nasal dripping, still survives after 8 days and is healthy-looking; and pathological anatomy and excisional biopsy show that each visceral organ is normal. The rabbit which is infected by the virus dies in 3 days. Thus, the protein can be used for preparation of medicaments for treating rabbit hemorrhagic disease.
Study Design. We retrospectively investigated the outcomes of 42 boys aged 0-19 years presenting with testicular masses. Excluding patients with incomplete records, they were treated at a tertiary referral center between May 2006 and November 2019, which were reviewed and retrospectively analyzed based on their age at the time of admission, presenting complaints, clinical and radiological findings, tumor markers, management, and follow-up. Pathology was centrally reviewed (C.H.) in patients with a tissue biopsy, but confirmation by a central review was not required before enrollment. This retrospective study was unanimously approved by the institutional review board of Chang Gung Memorial Hospital. Their parents or legal guardians provided written informed consent through an opt-out method on our hospital website following the ethical principles for medical research involving human subjects in Taiwan.

Data Collection. The evaluation included age at presentation, medical history, clinical characteristics, diagnostic procedures, treatment methods, histopathologic findings, and outcomes for every patient. All patients received the examinations of color Doppler ultrasonography of the testis and the abdomen, plain x-ray of the thorax, and serum α-fetoprotein (AFP) levels before operations. The AFP measurement is usually very high in newborns and does not decrease to normal adult levels until 8 months. Thus, the AFP levels of infants were evaluated according to reference ranges \[4,5\].

Surgical Technique All 42 tumors were treated surgically. We explored the groin through an inguinal incision. The testicle is gently grasped and exteriorized, and the spermatic cord and vessels within the tunica vaginalis are clamped. The resected tumor mass was sent for frozen section examination (FSE). Testis-sparing surgery was considered in patients with non-germ cell tumors. If the tumor had replaced the entire testis, a radical orchiectomy was taken. All tumors received histologic analysis. The optimal follow-up protocol included regular control visits with the physical examination, AFP measurements, and testicular sonography. Adjuvant chemotherapy was administered, depending on histopathology and TNM criteria for tumor classification. If non-germ cell tumors were assessed accurately on FSE, testis-sparing surgery could be considered an alternative treatment modality.
PURPOSE:To obtain a pack agent composition drying in a short time in blending the composition with water and applying the blend to the skin, showing a highly tense feeling, providing stain removing effects and wetting feeling, comprising glycyrrhizic acid or a derivative thereof and saccharide. CONSTITUTION:10-50wt.% glycyrrhizic acid or derivative thereof is blended with 50-90wt.% saccharide (e.g. D-mannose, d-mannitol, beta-lactose or beta-glucose) to give a composition for pack agent. When the composition is used, 1 pt.wt. of the composition is put in a container, blended with 0.4-0.8 pt.wt. water by a brush, thinly spread on the skin and a thin film is formed in a short time to give a highly tense feeling.
Placebo to omarigliptin administered orally once a week for 24 weeks (Phase A) followed by placebo to omarigliptin administered orally once a week plus metformin daily for an additional 30 weeks (Phase B). Open-label metformin was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
To provide dental plaster powder that has flowing properties, a cure time and strength of a hardened body suitable for dentistry for making a dental model by kneading with water and using it.SOLUTION: Dental plaster powder is configured such that gypsum dihydrate of 2-4 pts.wt., potassium sulfate of 0.5-3 pts.wt. and polycarboxylate-based water reducer of 0.05-0.8 pts.wt. are blended to gypsum hemihydrate of 100 pts.wt., and other additives are not contained beyond 0.3 pts.wt. in total. More preferably, a blending amount of the polycarboxylate-based water reducer may be 0.15-0.3 pts.wt. to the gypsum hemihydrate of 100 pts.wt., or the blending amount of the potassium sulfate may be equal to or more than 25% by weight of the gypsum dihydrate.SELECTED DRAWING: None
Monitoring changes in chlorophyll a (ChlFa) fluorescence during dehydration can provide insights into plant photosynthetic responses to climate change challenges, which are predicted to increase drought frequency. However, the limited knowledge of how ChlFa parameters respond to water deficit hinders the exploration of the photochemical mechanism of the photosynthetic process and the simulation of photosynthetic fluorescence models. Furthermore, how to track such responses of ChlFa parameters, especially at large scales, remains a challenge. In this study, we attempted to use spectral information reflected from leaves to follow the dynamic response patterns of ChlFa parameters of seven species under prolonged dehydration. The results showed that the investigated ChlFa parameters exhibited significant changes as dehydration progressed, with considerable variability among the different species as well as under different water conditions. This study also demonstrated that the integration of both spectral and water content information can provide an effective method for tracking ChlFa parameters during dehydration, explaining over 90% of the total variance in the measured ChlFa parameters. Collectively, these results should serve as a valuable reference for predicting the response of ChlFa parameters to dehydration and offer a potential method for estimating ChlFa parameters under drought conditions.
FIELD: medicine. SUBSTANCE: heparin is injected into cerebrospinal canal, its dose being 100 units per 1 kg of body mass. Usually within 24 h after injection significant clinic effect takes place. At different stages of the disease 1-4 endolumbar injections are to be carried out. Once a day subdermal injection of heparin is also carried out, its dose being as mentioned above. EFFECT: improves efficiency of treatment, decreases residual effects and lethality. 1 tbl
Some embodiments of the disclosure provide a diabetic retinopathy recognition system (S) based on fundus image. According to an embodiment, the system includes an image acquisition apparatus (1) configured to collect fundus images. The fundus images include target fundus images and reference fundus images taken from a person. The system further includes an automatic recognition apparatus (2) configured to process the fundus images from the image acquisition apparatus by using a deep learning method. The automatic recognition apparatus automatically determines whether a fundus image has a lesion and outputs the diagnostic result. According to another embodiment, the diabetic retinopathy recognition system (S) utilizes a deep learning method to automatically determine the fundus images and output the diagnostic result.
This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled study. It will evenly randomize 68 evaluable men and women adult patients with CRF in locally advanced or metastatic breast cancer who are candidates to start single-agent taxane chemotherapy (paclitaxel, nab-paclitaxel or docetaxel). CRF will be assessed at baseline on a scale from 0 - 10 (with 10 being most severe), enrolling any patient who report a score of 1 - 6. Recruitment will be competitive among the study sites, until the planned number of patients is randomized. Patients will be assigned (1:1) to receive either oral reparixin treatment (1200 mg t.i.d. - treatment group) or masked placebo t.i.d. (control group). Randomization will be stratified by site and according to the type of chemotherapy (paclitaxel vs docetaxel vs nab-paclitaxel). Sparse blood samples will be collected in the whole population for reparixin (and metabolites), docetaxel, nab-paclitaxel, paclitaxel PK analysis. Reparixin or placebo will be administered for 16 weeks or until disease progression, withdrawal of consent or unacceptable toxicity, whichever occurs first. Following the completion of the treatment, or after premature discontinuation during the double-blind phase the patients will be followed up for safety assessments for an additional 30 days after last study therapy administration and will be followed for progressive disease and survival until twelve months after last enrolled subject off treatment, or until trial is terminated for other reasons, whatever occurs first.

Number of Patients Sixty-eight (68) evaluable adult patients with CRF with locally advanced or metastatic breast cancer who are candidates to receive single-agent taxane chemotherapy will be included in the study. Assuming that 10% of subjects will not be evaluable for primary analysis, a total of approximately 76 subjects is expected to be enrolled.
Group 1 consists of diabetic patients free from diabetic retinopathy (45 eyes). OCT retinal GCC measurements.
Objective: Whether the retrograde or antegrade approach of stenting is superior in laparoscopic pyeloplasty remains a great controversy. Each technique has its advantages and disadvantages. We tried in this study to optimize the way of stenting, taking the advantages of both approaches and avoiding their disadvantages.

Methods: Between March 2013 and August 2021, 75 patients less than 15 years of age candidate for laparoscopic pyeloplasty were included in the study. All cases were done by the same surgeon in our institute. At first, a retrograde study was done, and an open-tip ureteric catheter was inserted just below the pelviureteric junction. Putting the ureteric catheter just below the pelviureteric junction makes the whole procedure easier. After proper dissection, the anterior wall of the pelvis is incised and continuing the ureteric spatulation on its lateral aspect. Before the complete division of the ureter, the first stitch is taken between the angle of ureteric spatulation and the lower angle of the pelvis. After completing the posterior wall anastomosis, a guide wire is introduced through the ureteric catheter, grasped gently, and pulled out through the uppermost port, and the ureteric catheter is then removed. With the proximal end of the guide wire passing through the upper port and its distal end coming outside the urethra, the DJ is passed in an antegrade manner while pulling on the urethral catheter balloon to close the bladder neck.
Sample of 880 children spontaneously recruited and representative of the French population according to the criteria defined for the study. Includes breastfed children.
Participants used the system in a sequential additive series. They used only the oil blend aromatically for 1 week, then the aromatic blend plus a topical stick application for 1 week, and then, for 4 weeks, the aromatic blend, the topical stick, and took 2 capsules of the dietary supplement nightly.
PURPOSE:To improve absorption in intestinal tracts and nutrient effects by hydrolyzing an aqueous solution of a protein with an endopeptidase and dipeptidyl carboxypeptidase(DPCP). CONSTITUTION:A culture obtained by culturing Bacillus subtilis HL521, strain, etc., is extracted and purified to afford DPCP having the following properties. Action; liberating peptides in dipeptide units of amino acids from the carboxy terminals of proteins. Optimum pH; 6.0-11.0. Action temperature; about 50 deg.C. Molecular weight; 110000 measured by a gel filtration method, etc. Endopeptidase, a proline-specific endopeptidase, derived from Flavobacterium meningosepticum, etc., and the above-mentioned DPCP are then added to an aqueous solution of soybean protein, etc., to carry out hydrolytic reaction at 25-60 deg.C for 8-72hr and afford a hydrolyzed solution. The resultant hydrolyzed solution ts subsequently purified to produce a low-molecular peptide composition having <=1000 molecular weight.
The present invention relates to a cosmetic composition for anti-oxidation, anti-inflammation, skin-whitening, or wrinkle prevention and alleviation comprising an extract of Trigonotis radicans var. sericea as an active ingredient. According to the present invention, an extract of Trigonotis radicans var. sericea has an anti-oxidant effect by inhibiting DPPH radicals, ABTS radicals, and TBARs and increasing PF, and has an anti-inflammatory effect by inhibiting hyaluronidase. In addition, the extract of Trigonotis radicans var. sericea has a wrinkle prevention and alleviation effect by inhibiting elastase or collagenase, and has a skin-whitening effect by inhibiting tyrosinase. Accordingly, the extract of Trigonotis radicans var. sericea can be usefully used in a pharmaceutical composition, a food composition, or a cosmetic composition having the above-mentioned biological activity.
The present invention relates to a kind of therapeutic field of tumor, particularly relate to Chrysomyiame gacephala (Fab.) goods for preparing the application in the treatment medicine of carcinoma of prostate, health product or food.The Chrysomyiame gacephala (Fab.) goods of the present invention are a kind of natural product, and Chrysomyiame gacephala (Fab.) goods effective ingredient is Chrysomyiame gacephala (Fab.) Scorpio, and modern medicine study proves: in Chrysomyiame gacephala (Fab.) containing protein, fat, chitosan, containing antibacterial peptide and 18 kinds of aminoacid.Including all effective ingredient of Chrysomyiame gacephala (Fab.) Scorpio in the Chrysomyiame gacephala (Fab.) dry powder of the present invention, Chrysomyiame gacephala (Fab.) extract is mainly with fatty acid and/or protein, polypeptide, aminoacid etc..It has been investigated that, Chrysomyiame gacephala (Fab.) goods can effectively suppress prostate cancer growth, and Chrysomyiame gacephala (Fab.) goods do not have drug resistance and the toxic and side effects thereof of chemotherapeutic conventional clinically.
Light pollution is a potential risk factor for intestinal health. Tryptophan plays an important role in the inhibition of intestinal inflammation. However, the mechanism of tryptophan in alleviating intestinal inflammation caused by long photoperiod is still unclear. This study investigated the anti-inflammatory effect of dietary tryptophan on intestinal inflammatory damage induced by long photoperiod and its potential mechanism in broiler chickens. We found that dietary tryptophan mitigated long photoperiod-induced intestinal tissue inflammatory damage and inhibited the activation of Nucleotide-Binding Oligomerization Domain, Leucine-Rich Repeat and Pyrin Domain-Containing 3 inflammasome. Moreover, dietary tryptophan significantly increased the relative abundance of Faecalibacterium, Enterococcus, and Lachnospiraceae_NC2004_group were significantly decreased the relative abundance of Ruminococcus_torques_group and norank_f_UCG-010 under the condition of long photoperiod (P < 0.05). The results of tryptophan targeted metabolomics show that tryptophan significantly increased indole-3-acetic acid (IAA) and indole-3 lactic acid (ILA), and significantly decreased xanthurenic acid (XA) under long photoperiod (P < 0.05). In conclusion, the results indicated that dietary tryptophan alleviates intestinal inflammatory damage caused by long photoperiod via the inhibition of Nucleotide-Binding Oligomerization Domain, Leucine-Rich Repeat and Pyrin Domain-Containing 3 inflammasome activation, which was mediated by tryptophan metabolites. Therefore, tryptophan supplementation could be a promising way to protect the intestine health under the condition of long photoperiod.
A medicinal agent exhibiting spasmolytic, litholytic, anti-inflammatory and antiseptic action comprises extracts of wild carrot, hop cones, origanum herb, peppermint oil, fir oil. Additionally it comprises magnesium alumomethasilicate (Neusilin UFL2), adjuvants for the formation of solid dosage form. A process for the preparation of medicinal agent exhibiting spasmolytic, litholytic, anti-inflammatory and antiseptic action involves mixing of active substances comprised of wild carrot extract, extract of hop cones, origanum herb extract, peppermint oil, fir oil with adjuvants. First fillers and magnesium alumomethasilicate (Neusilin UFL2) are mixed, then successively ricinic oil and complex thick extract comprising extracts of wild carrot, hop cones, origanum herb are loaded, mass is stirred, wet granulation is carried out, and wet granules prepared are transferred to the drying stage up to obtaining weight part of residual moisture in granulate from 1.5 to 3.0%. Simultaneously a mixture of ether oils is prepared by mixing fillers and magnesium alumomethasilicate (Neusilin UFL2) and addition of ricinic oil, peppermint oil and fir oil. The mass is stirred up to uniform distribution of oils over the mass, thereafter dry granules are added, and components are stirred, dry comminuted mixture is powdered, and prepared mass is transformed to single dosage form.
The present invention provides the use of a compound comprising: (i) a binding moiety which selectively binds to a protein listed in Table 1 and (ii) a further moiety in the treatment, imaging, diagnosis or prognosis of mantle cell lymphomas (MCL). Preferably, the binding moiety is an antibody or antigenbinding fragment thereof. Advantageously, the further moiety is a directly or indirectly cytotoxic moiety or a readily detectable moiety. The invention also provides methods of imaging MCL cells, methods of diagnosing or prognosing MCL in an individual and methods of treating an individual with MCL. A further aspect of the present invention provides a method of identifying cells associated with MCL, the method comprising analyzing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known MCL cells. Preferably, the cells to be tested are identified as MCL cells if the expression of one or more genes encoding a protein listed in Table 1 is upregulated compared to normal B-cells.
A dosage unit form, for the oral administration of medicaments and diagnostic agents, which swells without breaking when in contact with gastric juice, to such a size as to be mechanically ruptured on passage through the pyloric sphincter, comprises one or both of (a) a substance or mixture evolving gas on contact with gastric juice, and (b) a substance exerting an osmotic pressure in aqueous solution; sealed hermetically in a polymeric semi-permeable film which is resistant to attack by, but permeable to, gastric juice.  Suitable such films are made of gelatine, partially or wholly hydrolised polyvinyl acetate, vinyl acetate-vinyl alcohol copolymers, ethers or esters of cellulose, or plant mucilages, or mixtures of such materials, which have been hardened to give them the required resistant but semi-permeable properties.  Such hardening may be effected by treatment with formaldehyde (which is preferably afterwards removed by washing with ethanol or inactivated with ammonia or salts thereof) or by treatment with tannic acid, glutaraldehyde or ethylene oxide. Suitable gas-evolving substances are sodium bicarbonate, alone or admixed with citric or tartaric acid; osmotic-pressure-producing substances may be water-soluble salts (e.g. sodium or potassium chloride), or sugars (e.g. sucrose, lactose, or mannitol).  Forms taken by the dosage units are sealed capsules, preferably not less than 20 mms. in length, and made of the said materials; and easily disintegrated compressed tablets enclosed in a continuous film of these materials.  Examples are given for capsules containing the said ingredients with, as a medicament, disodium glycyrrhetinic acid hemisuccinate (carbenoxolone sodium); and, as a diagnostic agent, barium sulphate; together with ethyl hydroxyethyl cellulose as a thickening agent.